Amgen stock: Goldman Sachs raises target to USD 481.00

Published on 10/20/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Goldman Sachs set a USD 481.00 target on October 15, 2026. Amgen stock costs EUR 387.30 on October 20, 2026 at 4:42 p.m. CEST.

Goldman target updated

Goldman Sachs raised its Amgen target from USD 475.00 to USD 481.00 on October 15, 2026.
Amgen reported USD 10.05 billion in second-quarter 2026 revenue, up 9.50 percent year over year.
Amgen stock was trading at EUR 387.30 at Lang & Schwarz on October 20, 2026 at 4:42 p.m. CEST.
Amgen's next earnings release is scheduled for November 3, 2026.

Aquarellmalerei eines kalifornischen Firmencampus mit Glasgebäuden, Palmen und sanften Hügeln im Hintergrund — Amgen Inc. (ISIN US0311621009) wird hier als Aquarell-Landschaft mit kalifornischem Biotech-Campus dargestellt, Illustration mit AI erstellt.

Goldman Sachs raised its price target for Amgen from USD 475.00 to USD 481.00 on October 15, 2026, according to MarketScreener. The target is 10.46 percent above Amgen's USD 435.44 Nasdaq price on October 20, 2026 at 10:58 a.m. EDT. At Lang & Schwarz, Amgen was trading at EUR 387.30 on October 20, 2026 at 4:42 p.m. CEST.

Target moves above the market

The Goldman Sachs adjustment was the latest dated target change identified for Amgen within the current research window. The firm had lifted its target to USD 475.00 on October 13 before raising it again to USD 481.00 two days later, while the company remained covered by a broader Hold consensus in the same MarketScreener page.

The wider analyst picture is mixed. MarketBeat reported on October 18 that Wall Street Zen upgraded Amgen from Hold to Buy, while 30 analysts carried an average target of USD 387.93.

Revenue reached USD 10.05 billion

Amgen's latest reported quarter was the second quarter of 2026. Revenue reached USD 10.05 billion, up 9.50 percent from the comparable quarter, while net income was USD 2.38 billion and diluted earnings per share were USD 4.37, according to FinDog.

The same quarter produced USD 4.00 billion in operating cash flow, based on Amgen's reported financial statements for the period ended June 30, 2026. The revenue comparison is the more important operating signal because it places the target revision against a business that expanded at a double-digit rate on the latest reported quarter.

What comes next for Amgen?

Amgen's next earnings release is scheduled for November 3, 2026, after the market closes, according to FinDog. The event will provide the next scheduled test of the USD 481.00 target and the company's revenue trajectory.

Valuation and price range

Amgen's market capitalization was USD 235.4 billion on October 20, 2026, with a trailing P/E ratio of 27.06. Its 52-week range was USD 288.00 to USD 447.03, placing the Nasdaq price of USD 435.44 2.60 percent below the high.

Amgen trades in the healthcare sector and develops medicines across oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. The company is headquartered in Thousand Oaks, California, and employs 31,500 people.

Stock position after the target change

For investors, the key distinction is between the analyst target and the current trading level. Goldman Sachs now sees USD 481.00, while the latest Nasdaq price stood at USD 435.44 and the Lang & Schwarz euro quote was EUR 387.30. No recommendation follows from the target alone.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.